Platelets and platelet-derived vesicles as an innovative cellular and subcellular platform for managing multiple sclerosis

IntroductionMultiple sclerosis (MS) is a progressive inflammatory autoimmune disease that involves young individuals. The drug delivery systems now are available for this disease have chronic and non-targeted effects on the patients. Because of the presence of BBB (blood-brain-barrier), their concentration in the CNS (central nervous system) is low. Because of this flaw, it is critical to use innovative active targeted drug delivery methods.ResultPlatelets are blood cells that circulate freely and play an important role in blood hemostasis. In this review, we emphasize the various roles of activated platelets in the inflammatory condition to recruit other cells to the injured area and limit inflammation. Besides, the activated platelets in the different stages of the MS disease play a significant role in limiting the progression of inflammation in the peripheral area and CNS.DiscussionThis evidence indicates that a platelet-based drug delivery system can be an efficient biomimetic candidate for drug targeting to the CNS and limiting the inflammation in the peripheral and central areas for MS therapy.

Automated summary

Multiple sclerosis (MS) is a progressive inflammatory autoimmune disease that often occurs in young individuals. Current drug delivery systems for MS have limited efficacy due to the low concentration of drugs in the central nervous system (CNS) caused by the blood-brain barrier (BBB). Therefore, innovative active targeted drug delivery methods are critical for effective treatment.